TBPH — Theravance Biopharma Cashflow Statement
0.000.00%
Last trade - 00:00
- $429.63m
- $327.20m
- $57.42m
- 31
- 25
- 48
- 26
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -236 | -278 | -199 | -92.8 | -55.2 |
Depreciation | |||||
Deferred Taxes | |||||
Non-Cash Items | 37.2 | 60.3 | 25.2 | -140 | 31.3 |
Discontinued Operations | |||||
Unusual Items | |||||
Equity in Net Earnings/Losses | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -45.4 | -39.5 | -39.6 | 42.4 | -8.34 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Other Liabilities | |||||
Cash from Operating Activities | -238 | -250 | -208 | -187 | -27 |
Capital Expenditures | -3.18 | -6.62 | -3.41 | -0.572 | -2.49 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | -79.9 | 17.3 | 128 | 1,155 | -30.2 |
Sale of Business | |||||
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -83.1 | 10.7 | 124 | 1,154 | -32.7 |
Financing Cash Flow Items | 3.47 | 3.7 | 3.47 | 5.08 | 0.618 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 1.29 | 263 | 91.9 | -759 | -199 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -320 | 23.4 | 8.5 | 208 | -259 |